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Terminal deoxynucleotidyl transferase is an enzyme which has the unique 
property of polymerizing polydeoxynucleotides  onto a primer in the absence of a 
template (1, 2). This enzyme is found both in the thymus and the bone marrow of 
birds,  rodents,  and  humans  (3-7).  Whether  the  marrow  cells  that  contain 
terminal transferase are related to thymocytes, or are on a separate pathway of 
differentiation, is not yet known (7, 8). 
To determine the lineage of the murine bone marrow cells that have terminal 
transferase, we have investigated whether these cells have the antigen Thy-1 
which is  characteristic of T  cells  and thymocytes, or whether Thy-1  can be 
induced on the cells by treatment with thymopoietin (9). Thymopoietin  is known 
to induce a  set of characteristic T-cell markers including the Thy-1 alloantigen 
on the  surface of a  subpopulation of bone marrow cells committed to T-cell 
differentiation (prothymocytes) (10). Destruction of Thy-l-positive cells  after 
exposure to thymopoietin allows elimination of a  substantial fraction of those 
bone marrow cells that can repopulate an irradiated thymus (11). We find that 
such  an elimination after induction with the  thymic polypeptide removes a 
substantial amount of terminal transferase from the bone marrow cell popula- 
tion, suggesting that at least one-half of the marrow cells bearing this enzyme 
are related to those found in the thymus. 
Materials and Methods 
Mice.  C57BL6/J and A/J mice from The Jackson Laboratory, Bar Harbor, Maine, were used. 
Cell Preparation.  Thymocytes  and marrow  lymphocytes  extracted from femoral  and tibial 
plugs  were  suspended  in  phosphate-buffered  saline  (PBS)-5%  fetal  calf serum  (FCS)  (Micro- 
biological Associates, Bethesda, Md.) as described (7). 
Induction of Cytotoxic Antibodies.  Bovine thymopoietin was prepared as described (9). It was 
dissolved in PBS-2% FCS at a final concentration of 500 ng/ml. In a typical experiment cells were 
incubated at 4  ×  107/ml for 2.5 h  at 37°C, then washed twice with PBS-2% FCS. 
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Complement-Mediated Cytotoxicity.  Anti-Thy-l.2 was either a gift of Dr. E. A. Boyse (Memo- 
rial Sloan-Kettering Cancer Center,  New York) or was prepared as described (12). The method of 
treatment of lymphoid cells with anti-Thy-l.2 serum and complement (C) has been described 
previously (12). In a representative experiment, l0  s cells/ml were incubated with Thy-l.2 antise- 
rum at a dilution of 1:50 at room temperature for 30 min, washed once, and incubated for a further 
1/2 h with rabbit C (1:10 dilution) at 37°C. The cells were then pelleted and washed several times. 
In cases where viability was leas than 85%, Ficol-Hypaque centrifugation was used to remove dead 
cells (13), before the cells were pelleted and frozen at -70°C. 
Extraction  of Terminal Transferase.  The procedure has been previously described (7), except 
that  in  order to inhibit protease activity the  inhibitor phenylmethylsulfonylfluoride  (PMSF) 
(Sigma Chemical Co., St. Louis, Mo.) was introduced at the time of the first thawing of the sample 
at a concentration of 4 gmol/108 cells in 4.3 mmol of ethanol (per 5-ml vol). 
PhosphoceUulose Chromatography.  The procedure was modified (5, 7) to examine the smaller 
amounts of activity present in the bone marrow. A 4 cm column, rather than 12 cm was used, the 
gradient was only 25 ml in total vol, and fractions of 0.25-0.32 ml size were collected. Terminal 
transferase assays were done as previously described (5, 7). 
Results 
To  determine  the  effect  of anti-Thy-l.2  and  C  upon  terminal  transferase 
activity in thymocytes, the amount of terminal transferase in the cells remain- 
ing after treatment was measured and expressed as specific activity of enzyme 
per 109 remaining viable cells.  Although anti-Thy-l.2 serum and C  killed most 
thymocytes (94% were specifically killed by antiserum in exp.  1,  Table I), the 
remaining cells had the same activity per cell of terminal transferase as cells 
treated with normal mouse serum (Table I, lines 1 and 2). This level of enzyme 
activity is similar to that in untreated thymocytes (reference 7 and unpublished 
data).  The few anti-Thy-l.2-resistant cells are therefore not different from the 
average normal thymocyte population. 
The effect of anti-Thy-l.2 treatment on the terminal transferase content of the 
marrow lymphocytes was studied using the same protocol used for the thymo- 
cytes.  In  the  marrow  most  cells  lack  detectable  terminal  transferase  (P.  C. 
Kung,  unpublished  results)  and  therefore  if the  2-5%  Thy-l-positive cells  in 
bone marrow (10,  11) were responsible for all of the marrow terminal transfer- 
ase, anti-Thy-l.2 serum should greatly reduce the specific activity of the enzyme 
in marrow cells. On the contrary, terminal transferase activity was unchanged 
by treatment of marrow cells with anti-Thy-l.2 and C  (Table I, lines 1,  2, 4, 7, 
and 8).  The majority of the enzyme-positive cells of the marrow therefore lack 
Thy-1 determinants on their surface. 
To determine if Thy-1 determinants could be induced onto the surface of the 
terminal  transferase-containing  cells,  marrow cells were treated with  thymo- 
poietin for 2-3 h. When the thymopoietin-treated cells were exposed to anti-Thy- 
1.2 antibody, the terminal transferase specific activity was reduced by over 50% 
(Table I, lines 3, 6, and 10).  Because treatment with thymopoietin alone did not 
alter the terminal transferase content of the marrow cells (Table I, lines 5 and 9) 
it  appears  that  thymopoietin  induced  Thy-l.2  expression  on  the  surface  of a 
significant  portion  of the  terminal  transferase-containing  cells,  thus  making 
them susceptible to the antiserum. The number of cells specifically killed in the 
marrow by anti-Thy-l.2 treatment was impossible to determine with accuracy 
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TABLE  I 
Effect of Antibody Treatment on Cell Number and Terminal Transferase Levels in 
C57BL/6J and A/J Mice 
Inductive treatment  Postinduction  antiserum  +  C 
Terminal  transferase  remaining 
Bone marrow 
Thymocytes  lymphseytes 
Exp.  1, C57BL]6J 
Exp. 2, A/J 
Exp. 3, A/J 
U/IO  9 cells 
None  Normal mouse serum  2.69  0.208 
None  Anti-Thy-l:2  2.50  0.188 
Thymopoietin  Anti-Thy-  1.2  -  0.061 
None  Anti-Thy- 1.2  -  0.216 
Thymopoietin  Normal  mouse  serum  -  0.204 
Thymopoietin  Anti-Thy-l.2  -  O.  107 
None  Normal mouse serum  -  0.206 
None  Anti-Thy-  1.2  -  0.243 
Thymopoietin  Normal mouse serum  -  0.198 
Thymopoietin  Anti-Thy-  1.2  -  0.102 
and 2, Table I) 5-10% specific killing over the C background could be detected, 
but in experiment three (Table I) no specific killing over background was seen. 
We have  previously noted  that  thymocytes contain  two forms of terminal 
transferase,  one of which elutes from phosphocellulose at lower salt concentra- 
tion than the other (7, 8). We have also found that well-defined two-peak profiles 
of elution  from  phosphocellulose  are  found  most  reproducibly  if a  protease 
inhibitor, PMSF, is added to the extraction medium (unpublished observations). 
Even using the protease inhibitor,  bone marrow terminal  transferase  did not 
give a two-peak profile of elution (Fig. 1). The majority of the enzyme, however, 
elutes in the region of the column where the low salt, "peak r' form of terminal 
transferase  elutes  (compare  figures  in  reference  7).  Treatment  of cells  with 
thymopoietin followed by anti-Thy-l.2 serum produced a generalized decrease of 
terminal  transferase  throughout  the  phosphocellulose elution profile  (Fig.  1) 
while  neither  anti-Thy-l.2  treatment  alone  or  thymopoietin  alone  had  any 
reproducible effect.  In the  experiment  of Fig.  1,  a  75%  reduction  of terminal 
transferase was produced by thymopoietin plus anti-Thy-l.2  treatment;  this is 
the largest effect we have seen. 
Table II presents the averaging of the results of five experiments.  It is clear 
that although there is no significant loss of marrow terminal transferase after 
anti-Thy-l.2 treatment,  or C treatment, of mouse bone marrow cells, the elimi- 
nation of Thy-l.2 cells after induction with thymopoietin results in a significant 
decrease of terminal trausferase. This loss represents an average of 58% with a 
range of loss of enzyme from 50 to 75%. 
Discussion 
In order to investigate the nature of the bone marrow cells containing termi- 
nal  transferase,  we have taken advantage of the  ability to induce a  thymus- 
specific antigen,  Thy-1,  on bone marrow  cells using  the  thymic polypeptide, 
thymopoietin.  After this treatment,  cells now expressing the  antigen  can be 
killed  by cytotoxic antibody treatment.  As  our results  show,  this  leads  to  a 
destruction of marrow cells carrying terminal transferase.  Therefore, a  signifi- 546 
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Fza.  1.  Elimination  of terminal transferase-bearing cells in bone marrow by induction 
and cytotoxic antibodies. C',  C-treated samples. Anti-Thy-l.2 treated with antiserum. 
Treatment is described in the Materials and Methods. See text for protocol. 
TABLE II 
Average Results of Induction and Cytotoxic Elimination of Terminal 
Transferase Levels in Marrow Cells 
Terminal transferase 
Inductive treatment  Postinductive treatment  remaining* 
U/IO ~ cells 
None  None  0.208 
None  Normal mouse serum  0.216 
None  Anti-Thy-l.2 + C  0.191 
Thymopoietin  Normal  mouse  serum  0.219 
+  complement 
Thymopoietin  Anti-Thy-l.2 +  C  0.090 
*Each value represents  average of  three  or  four  determinations, with  standard deviation less  than 20%. 
cant portion of the cells in the mouse marrow which bear terminal transferase 
must already be committed to the T-cell pathway. Since thymopoietin appears to 
selectively induce a population already committed to development along the T- 
cell  pathway  (14),  and  does  not  affect  lymphocytes  destined  for  the  B-cell 
pathway,  the  population of cells  we  have  eliminated  probably represents  a 
portion of the prothymocyte population of the marrow. 
In earlier papers (7, 8, 15) it has been suggested that the marrow cells bearing 
terminal transferase are related developmentally to the thymus cells which bear 
high levels of this enzyme. Here, we present data supporting this supposition. 
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the T-cell pathway is uncertain. In our experiments we may not have eliminated 
all the measurable terminal transferase because of the incompleteness of our 
induction or incompleteness of killing by cytotoxic antibody, or both. We are 
unable to settle this question given the current limits in our technique. How- 
ever, we are investigating the possibility that terminal transferase may also be 
present in pre-B cells using an experimental approach similar to that described 
here. 
We can say from our results that terminal transferase is a valuable marker for 
studying T-cell development. It is now the earliest known property of cells that 
can undergo thymus-dependent development, and it clearly disappears before 
the final maturation of the T cell to a circulating lymphocyte (15, 16). Studying 
the appearance and disappearance of this enzyme in selected cell populations 
may help explain the development of function by T  cells. 
We are very grateful for the technical and theoretical advice and antibody supplied by Doctors E. 
A. Boyse and M. P. Scheid. These experiments would not have been possible without the technical 
assistance of Joan Hugenberger and Laila Boudreau. 
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